knowledge -WSS

knowledge

author：leisure time 2025-09-30 00:36:40 - browse：615

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

explore

Wikipedia

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Why Eli Lilly’s earnings didn’t quite live up to the hype

Abbott's new heart device gets FDA advisory panel nod

Juul documents reveal insider tactics on political lobbying

Long Covid research funding gets a major boost from NIH

Elevance, private equity launch primary care company

focus

knowledge

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

What nurses really want: sufficient staffing for patient care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Abbott's new heart device gets FDA advisory panel nod

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: What to know about H5N1 bird flu

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu outbreak in cows is latest avian flu curveball

After affirmative action ruling, medical educators look to 'holistic review'

Long Covid research funding gets a major boost from NIH

explore

Long Covid research funding gets a major boost from NIH

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Use wet bulb globe temperature, not heat index, to protect workers

After gene therapy, two congenitally deaf children hear for the first time

CDC wastewater surveillance dashboard to track bird flu hotspots

AMAs digital advisors table RPM coding reform proposal, again

explore

Wikipedia

hotspot

entertainment